Vertex Pharmaceuticals Inc(VRTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | NDX, S&P 500 | P/E | 30.32 | EPS (ttm) | 17.19 | Insider Own | 0.22% | Shs Outstand | 253.3M | Perf Week | -4.84% |
| Market Cap | 132.09B | Forward P/E | 24.59 | EPS next Y | 12.99% | Insider Trans | -5.45% | Shs Float | 252.9M | Perf Month | -0.53% |
| Enterprise Value | 126.21B | PEG | 2.19 | EPS next Q | 4.8 | Inst Own | 98.19% | Short Float | 1.64% | Perf Quarter | 16.91% |
| Income | 4.41B | P/S | 10.4 | EPS this Y | 1.92% | Inst Trans | 0.13% | Short Ratio | 2.8 | Perf Half Y | 4.4% |
| Sales | 12.70B | P/B | 6.52 | EPS next 5Y | 11.22% | ROA | 17.12% | Short Interest | 4.15M | Perf YTD | 14.95% |
| Book/sh | 79.92 | P/C | 16.8 | EPS past 3/5Y | 6.12% 8.28% | ROE | 23.54% | 52W High | -6.98% ($560.25) | Perf Year | 31.44% |
| Cash/sh | 31.02 | P/FCF | 34.8 | Sales past 3/5Y | 11.34% 14.23% | ROIC | 19.82% | 52W Low | 39.28% ($374.17) | Perf 3Y | 51.92% |
| Dividend Est. | - | EV/EBITDA | 24.08 | EPS Y/Y TTM | 22.53% | Gross Margin | 86.12% | Volatility(W/M) | 1.91% 2.38% | Perf 5Y | 177.07% |
| Dividend TTM | - | EV/Sales | 9.94 | Sales Y/Y TTM | 11.45% | Oper. Margin | 39.54% | ATR (14) | 13.59 | Perf 10Y | 456.31% |
| Dividend Ex-Date | - | Quick Ratio | 2.74 | EPS Q/Q | 8.02% | Profit Margin | 34.69% | RSI (14) | 46.35 | Recom | 1.64 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.19 | Sales Q/Q | 11.99% | SMA20 | -3.24% ($538.6) | Beta | 0.28 | Target Price | $574.32 |
| Payout | - | Debt/Eq | 0.1 | Earnings | 2026/8/3 | SMA50 | 2.2% ($509.93) | Rel Volume | 0.63 | Prev Close | $528.9 |
| Employees | 6400 | LT Debt/Eq | 0.1 | EPS/Sales Surpr. | -0.23% 3.2% | SMA200 | 11.57% ($467.11) | Avg Volume(3M) | 1.48M | Price | $521.15 |
| IPO | 1991/7/24 | Option/Short | Yes/Yes | Trades | 24221 | Volume | 929,141 | Change | -1.47% |
Company
VRTX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 A global leading biotech company specializing in cystic fibrosis therapeutics. Founded in 1989 and headquartered in Boston, Massachusetts, this biotech group has been advancing its cystic fibrosis targeted therapy portfolio alongside the expansion of its new pipeline.
Over the past 1 year, on the higher side
7% below its 1-year high.
VRTX makes money exceptionally well
39.54% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +1.9% this year.
Tap to view numbers
The price looks about right
Trading at 30.3 times earnings.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Would have changed by +51.9% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 98.2%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBH 0.09%
TBXU 0.08%
IBB 0.08%
IBBQ 0.07%
LSGR 0.05%It is the largest in the industry
Based on market cap of $132B.
VRTX $132B PER 30.3
REGN $83B PER 20.0
ARGX $63B PER 38.2
MRNA $54B PER -
FAQ
What kind of company is VRTX?
VRTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of VRTX?
The market cap of VRTX is approximately $132.1B, ranking 118 within its sector.
What is the P/E ratio of VRTX?
VRTX has a P/E ratio of approximately 30.3x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for VRTX?
VRTX has recorded a 52-week high of $560.25 and a low of $374.17.
